

**Date:** February 04, 2026

To,  
 Sr. General Manager  
 Listing Department  
**BSE Limited**  
 Pheroze Jeejeebhoy Towers  
 Dalal Street  
 Mumbai – 400 001

**BSE Scrip Code: 544319**

To,  
 Sr. General Manager  
 Listing Department  
**National Stock Exchange of India Limited**  
 Exchange Plaza, C-1, Block G  
 Bandra Kurla Complex  
 Bandra (E), Mumbai – 400 051

**NSE Symbol: SENORES**

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").**

**Ref: Issue and allotment of 11,70,000 convertible equity warrants by way of preferential issue on private placement basis by Senores Pharmaceuticals Limited (the "Company") in terms of Chapter V of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended ("SEBI ICDR Regulations").**

Dear Sir/Madam,

In terms of Regulation 30 read with Schedule III of the SEBI LODR Regulations, Chapter V of SEBI ICDR Regulations and in continuation to our earlier intimations dated January 09, 2026 regarding the Notice of Extra-Ordinary General Meeting ("EGM") dated January 07, 2026, we would like to submit certain amendments, clarifications and additional disclosures to Item No. 1 of the explanatory statement annexed to the EGM Notice dated January 07, 2026 ("Explanatory Statement"), as mentioned herein:

1. On page no. 19 of EGM notice, the first proviso of Explanatory Statement shall stand replaced and be read as follows:

"Provided that if the Articles of Association of the issuer provide for a method of determination, which results in a floor price higher than that determined under these regulations, then the same shall be considered as the floor price for specified securities to be allotted pursuant to the preferential issue. – As per the Articles of Association of the Company, the Company has obtained a valuation report dated January 07, 2026, from Maitri Valuation Private Limited, an independent registered valuer (IBBI Registration No.: IBBI/RV-E/11/2023/184) to determine the fair value of the Equity Shares proposed to be issued on conversion of Warrants issued under the preferential allotment. No specific method of valuation has been prescribed under the Articles of Association of the Company."

2. The rationale for submitting the Valuation Report and assigning 100% weightage to market approach is as follows:

**Rationale for submitting the valuation report:**

Since the quantum of the Proposed Issue is less than 5% of the post-issue fully diluted share capital of the Company, the provisions of Regulation 166A of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations"), which mandates a valuation report by an independent registered valuer for preferential issues, are not applicable.

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

However, the Articles of Association of the Company states that the Company is required to obtain a valuation report from a registered valuer for determining the floor price. Therefore, in accordance with proviso to Regulation 164(1) of the SEBI ICDR Regulations the valuation report dated January 07, 2026 has been issued by registered valuer to the Company for determining the fair market value of the Equity Shares proposed to be issued on conversion of the Warrants.

**Rationale for assigning 100% weightage to market approach:**

Registered valuer considered the following valuation parameters for determining the fair market value of the Equity Shares proposed to be issued on conversion of Warrants proposed to be issued:

1. Asset Approach – Net Asset Value Method
2. Income Approach – Profit Earning Capacity Value Method
3. Market Approach – Market Price Method

As the value calculated as per the Profit Earning Capacity Value Method and Net Asset Value Method are less than the value as per Market Price Method, which is also the Floor Price as per SEBI ICDR Regulations, registered valuer provided nil weightage to Profit Earning Capacity Value Method and Net Asset Value Method. Further the value recommended by registered valuer for the preferential issue under consideration is ₹ 812.00/- per share as determined under the market approach.

All other contents of the EGM Notice together with the explanatory statement thereof, save and except as modified or supplemented by the Clarification, shall remain unchanged.

The Clarification is available on the website of the Company at [senorespharma.com](http://senorespharma.com) and on the website of the Stock Exchanges at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

We request you to kindly take note of the clarification and consider the revised details as final and accurate.

**For, Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**  
Company Secretary and Compliance Officer  
ICSI Membership No.: F11464

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)  
W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263